This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure (PARADIGM-HF)
July 13, 2016 updated by: Novartis Pharmaceuticals
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =< 35%).
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
8442
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Buenos Aires, Argentina
- Novartis Investigative Site
-
Buenos Aires, Argentina, C1405BCH
- Novartis Investigative Site
-
Buenos Aires, Argentina, C1090AAH
- Novartis Investigative Site
-
Buenos Aires, Argentina, C1209ABD
- Novartis Investigative Site
-
Buenos Aires, Argentina, C1426EGR
- Novartis Investigative Site
-
Cordoba, Argentina, X5016KEH
- Novartis Investigative Site
-
Cordoba, Argentina, X5003DCP
- Novartis Investigative Site
-
Cordoba, Argentina, X5009BSN
- Novartis Investigative Site
-
Cordoba, Argentina, X5000AAW
- Novartis Investigative Site
-
Cordoba, Argentina, X5016KET
- Novartis Investigative Site
-
Cordoba, Argentina, 5000
- Novartis Investigative Site
-
Cordoba, Argentina, X5000AAX
- Novartis Investigative Site
-
Cordoba, Argentina, X5000BSQ
- Novartis Investigative Site
-
Cordoba, Argentina, X5014OPO
- Novartis Investigative Site
-
Corrientes, Argentina, W3400
- Novartis Investigative Site
-
Corrientes, Argentina, W3400CLH
- Novartis Investigative Site
-
Córdoba, Argentina, X5006IKK
- Novartis Investigative Site
-
Formosa, Argentina, P3600
- Novartis Investigative Site
-
Formosa, Argentina, P3634XAR
- Novartis Investigative Site
-
Mendoza, Argentina, M5500CHC
- Novartis Investigative Site
-
Mendoza, Argentina, M5500AAJ
- Novartis Investigative Site
-
Mendoza, Argentina, M5500EOB
- Novartis Investigative Site
-
Salta, Argentina, A4400ANG
- Novartis Investigative Site
-
San Juan, Argentina, J5402DIL
- Novartis Investigative Site
-
San Luis, Argentina, D5702JRS
- Novartis Investigative Site
-
Santa Fe, Argentina, S3000FWO
- Novartis Investigative Site
-
Santa Fe, Argentina, S3000EOZ
- Novartis Investigative Site
-
Santiago del Estero, Argentina, G4200AQK
- Novartis Investigative Site
-
-
Buenos Aires
-
Caba, Buenos Aires, Argentina, C1221ADC
- Novartis Investigative Site
-
Caba, Buenos Aires, Argentina, C1425DTG
- Novartis Investigative Site
-
Ciudad Autonoma de Bs As, Buenos Aires, Argentina, C1119ACN
- Novartis Investigative Site
-
Lanus, Buenos Aires, Argentina, B1824ABE
- Novartis Investigative Site
-
Mar del Plata, Buenos Aires, Argentina, B7600FZN
- Novartis Investigative Site
-
Mar del Plata, Buenos Aires, Argentina, B7600DHK
- Novartis Investigative Site
-
Mar del Plata, Buenos Aires, Argentina, B7600FZD
- Novartis Investigative Site
-
Munro, Buenos Aires, Argentina, B1605DSX
- Novartis Investigative Site
-
Pilar, Buenos Aires, Argentina, B1629AHJ
- Novartis Investigative Site
-
Quilmes, Buenos Aires, Argentina, B1878DVB
- Novartis Investigative Site
-
San Isidro, Buenos Aires, Argentina, B1642DJG
- Novartis Investigative Site
-
Zarate, Buenos Aires, Argentina, 2800
- Novartis Investigative Site
-
-
Capital Federal
-
Caba, Capital Federal, Argentina, C1179AAB
- Novartis Investigative Site
-
Caba, Capital Federal, Argentina, C1425FVH
- Novartis Investigative Site
-
-
Chubut
-
Trelew, Chubut, Argentina, U9100AQR
- Novartis Investigative Site
-
-
Jujuy
-
San Salvador de Jujuy, Jujuy, Argentina, Y4600ABF
- Novartis Investigative Site
-
-
Rio Negro
-
Cipolletti, Rio Negro, Argentina, 8324
- Novartis Investigative Site
-
-
San Juan
-
Buenos Aires, San Juan, Argentina
- Novartis Investigative Site
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina, S2000AII
- Novartis Investigative Site
-
Rosario, Santa Fe, Argentina, S200CXP
- Novartis Investigative Site
-
Rosario, Santa Fe, Argentina, 2000
- Novartis Investigative Site
-
Rosario, Santa Fe, Argentina, S2002KDS
- Novartis Investigative Site
-
Rosario, Santa Fe, Argentina, S2001SBL
- Novartis Investigative Site
-
-
Tucuman
-
San Miguel de Tucuman, Tucuman, Argentina, T4000EBR
- Novartis Investigative Site
-
San Miguel de Tucuman, Tucuman, Argentina, T4000JCU
- Novartis Investigative Site
-
San Miguel de Tucuman, Tucuman, Argentina, T4000IIH
- Novartis Investigative Site
-
-
-
-
-
Antwerpen, Belgium, 2060
- Novartis Investigative Site
-
Baudour, Belgium, 7331
- Novartis Investigative Site
-
Bonheiden, Belgium, 2820
- Novartis Investigative Site
-
Brasschaat, Belgium, 2930
- Novartis Investigative Site
-
Brugge, Belgium, 8000
- Novartis Investigative Site
-
Brussel, Belgium, 1090
- Novartis Investigative Site
-
Brussels, Belgium, 1070
- Novartis Investigative Site
-
Gent, Belgium, 9000
- Novartis Investigative Site
-
Hasselt, Belgium, 3500
- Novartis Investigative Site
-
Heusden-Zolder, Belgium, 3550
- Novartis Investigative Site
-
La Louvière, Belgium, 7100
- Novartis Investigative Site
-
Leuven, Belgium, 3000
- Novartis Investigative Site
-
Ottignies, Belgium, 1340
- Novartis Investigative Site
-
Ronse, Belgium, 9600
- Novartis Investigative Site
-
-
-
-
BA
-
Salvador, BA, Brazil, 41810-010
- Novartis Investigative Site
-
Salvador, BA, Brazil, 40140-110
- Novartis Investigative Site
-
-
DF
-
Brasilia, DF, Brazil, 70390-903
- Novartis Investigative Site
-
-
GO
-
Goiania, GO, Brazil, 74223-130
- Novartis Investigative Site
-
Goiania, GO, Brazil, 74605-050
- Novartis Investigative Site
-
Goiania, GO, Brazil, 74823-470
- Novartis Investigative Site
-
-
MA
-
Sao Luis, MA, Brazil, 65020-070
- Novartis Investigative Site
-
-
MG
-
Belo Horizonte, MG, Brazil, 30150-221
- Novartis Investigative Site
-
Belo Horizonte, MG, Brazil, 20180-090
- Novartis Investigative Site
-
Uberlândia, MG, Brazil, 38400-368
- Novartis Investigative Site
-
-
PA
-
Belem, PA, Brazil, 66087-660
- Novartis Investigative Site
-
-
PE
-
Recife, PE, Brazil, 50100-030
- Novartis Investigative Site
-
Recife, PE, Brazil, 50100-130
- Novartis Investigative Site
-
Recife, PE, Brazil, 52051 - 38
- Novartis Investigative Site
-
-
PR
-
Curitiba, PR, Brazil, 80730-150
- Novartis Investigative Site
-
-
RJ
-
Rio de Janeiro, RJ, Brazil, 21941-590
- Novartis Investigative Site
-
Rio de Janeiro, RJ, Brazil, 22280-020
- Novartis Investigative Site
-
Rio de Janeiro, RJ, Brazil, 22261-010
- Novartis Investigative Site
-
-
RN
-
Natal, RN, Brazil, 59020-035
- Novartis Investigative Site
-
-
RS
-
Passo Fundo, RS, Brazil, 99010-080
- Novartis Investigative Site
-
Porto Alegre, RS, Brazil, 90880-480
- Novartis Investigative Site
-
Porto Alegre, RS, Brazil, 90620-001
- Novartis Investigative Site
-
Porto Alegre, RS, Brazil, 92425900
- Novartis Investigative Site
-
-
SP
-
Marilia, SP, Brazil, 17515-000
- Novartis Investigative Site
-
Ribeirao Preto, SP, Brazil, 14055-370
- Novartis Investigative Site
-
Santo Andre, SP, Brazil, 09190-615
- Novartis Investigative Site
-
Santo Andre, SP, Brazil, 09030-640
- Novartis Investigative Site
-
Sao Jose do Rio Preto, SP, Brazil, 15015-750
- Novartis Investigative Site
-
Sao Paulo, SP, Brazil, 01327-010
- Novartis Investigative Site
-
São Paulo, SP, Brazil, 05403-000
- Novartis Investigative Site
-
São Paulo, SP, Brazil, 01506-000
- Novartis Investigative Site
-
Votuporanga, SP, Brazil, 15500-003
- Novartis Investigative Site
-
-
-
-
-
Burgas, Bulgaria, 8000
- Novartis Investigative Site
-
Haskovo, Bulgaria, 6300
- Novartis Investigative Site
-
Pazardzhik, Bulgaria, 4400
- Novartis Investigative Site
-
Pleven, Bulgaria, 5800
- Novartis Investigative Site
-
Plovdiv, Bulgaria, 4002
- Novartis Investigative Site
-
Plovdiv, Bulgaria, 4000
- Novartis Investigative Site
-
Plovdiv, Bulgaria, 4004
- Novartis Investigative Site
-
Russe, Bulgaria, 7002
- Novartis Investigative Site
-
Shumen, Bulgaria, 9700
- Novartis Investigative Site
-
Silistra, Bulgaria, 7500
- Novartis Investigative Site
-
Sofia, Bulgaria, 1527
- Novartis Investigative Site
-
Sofia, Bulgaria, 1309
- Novartis Investigative Site
-
Sofia, Bulgaria, 1431
- Novartis Investigative Site
-
Sofia, Bulgaria, 1202
- Novartis Investigative Site
-
Sofia, Bulgaria, 1233
- Novartis Investigative Site
-
Sofia, Bulgaria, 1606
- Novartis Investigative Site
-
Sofia, Bulgaria, 1505
- Novartis Investigative Site
-
Stara Zagora, Bulgaria, 6000
- Novartis Investigative Site
-
Varna, Bulgaria, 9010
- Novartis Investigative Site
-
Veliko Tarnovo, Bulgaria, 5000
- Novartis Investigative Site
-
-
-
-
British Columbia
-
New Westminster, British Columbia, Canada, V3L 3W4
- Novartis Investigative Site
-
Surrey, British Columbia, Canada, V3V 1N1
- Novartis Investigative Site
-
Victoria, British Columbia, Canada, V8R4R2
- Novartis Investigative Site
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1G 1A7
- Novartis Investigative Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Novartis Investigative Site
-
-
Ontario
-
Cambridge, Ontario, Canada, N1R 6V6
- Novartis Investigative Site
-
Kitchener, Ontario, Canada, N2M 5N4
- Novartis Investigative Site
-
London, Ontario, Canada, N6A 5A5
- Novartis Investigative Site
-
Oshawa, Ontario, Canada, L1J 2K1
- Novartis Investigative Site
-
Sudbury, Ontario, Canada, P3E 3B8
- Novartis Investigative Site
-
Toronto, Ontario, Canada, M5G 2N2
- Novartis Investigative Site
-
Toronto, Ontario, Canada, M5B 1W8
- Novartis Investigative Site
-
Toronto, Ontario, Canada, M5G 1X5
- Novartis Investigative Site
-
Weston, Ontario, Canada, M9N 1W4
- Novartis Investigative Site
-
-
Quebec
-
Granby, Quebec, Canada, J2G 1T7
- Novartis Investigative Site
-
Lachine, Quebec, Canada, H8S 2E4
- Novartis Investigative Site
-
Laval, Quebec, Canada, H7M 3L9
- Novartis Investigative Site
-
Longueuil, Quebec, Canada, J4M 2X1
- Novartis Investigative Site
-
Lévis, Quebec, Canada, G6V 4Z5
- Novartis Investigative Site
-
Montreal, Quebec, Canada, H2W 1T8
- Novartis Investigative Site
-
Montreal, Quebec, Canada, H3T 1E2
- Novartis Investigative Site
-
Montreal, Quebec, Canada, H3G 1A4
- Novartis Investigative Site
-
Montreal, Quebec, Canada, H3A 1A1
- Novartis Investigative Site
-
Sainte-Foy, Quebec, Canada, G1V 4G5
- Novartis Investigative Site
-
Sherbrooke, Quebec, Canada, J1G-2E8
- Novartis Investigative Site
-
St-Georges Beauce, Quebec, Canada, G5Y 4T8
- Novartis Investigative Site
-
Thetford Mines, Quebec, Canada, G6G 2V4
- Novartis Investigative Site
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4P 0w5
- Novartis Investigative Site
-
-
-
-
-
Santiago, Chile
- Novartis Investigative Site
-
Santiago, Chile, 8360160
- Novartis Investigative Site
-
Talcahuano, Chile
- Novartis Investigative Site
-
-
Araucania
-
Temuco, Araucania, Chile, 4780000
- Novartis Investigative Site
-
-
Bio Bio
-
Los Angeles, Bio Bio, Chile, 4440000
- Novartis Investigative Site
-
-
Cautin
-
Temuco, Cautin, Chile
- Novartis Investigative Site
-
-
Region Metropolitana
-
Santiago, Region Metropolitana, Chile
- Novartis Investigative Site
-
-
Santiago
-
San Miguel, Santiago, Chile, 8900000
- Novartis Investigative Site
-
Vitacura, Santiago, Chile, 7630000
- Novartis Investigative Site
-
-
-
-
-
Baotou, China, 014040
- Novartis Investigative Site
-
Beijing, China, 100044
- Novartis Investigative Site
-
Beijing, China, 100730
- Novartis Investigative Site
-
Beijing, China, 100029
- Novartis Investigative Site
-
Chongqing, China, 400037
- Novartis Investigative Site
-
Shanghai, China, 200080
- Novartis Investigative Site
-
-
Beijing
-
Beijing, Beijing, China, 100037
- Novartis Investigative Site
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150001
- Novartis Investigative Site
-
-
Hunan
-
Changsha, Hunan, China, 410003
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Novartis Investigative Site
-
Nanjing, Jiangsu, China
- Novartis Investigative Site
-
Nanjing, Jiangsu, China, 210009
- Novartis Investigative Site
-
-
Liaoning
-
Shenyang, Liaoning, China, 110003
- Novartis Investigative Site
-
-
Shanxi
-
Xi'an, Shanxi, China, 710061
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Novartis Investigative Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Novartis Investigative Site
-
-
-
-
-
Barranquilla, Colombia
- Novartis Investigative Site
-
Bogotá, Colombia
- Novartis Investigative Site
-
Cali, Colombia
- Novartis Investigative Site
-
Cartegena, Colombia
- Novartis Investigative Site
-
Florida Blanca, Colombia
- Novartis Investigative Site
-
Medellín, Colombia
- Novartis Investigative Site
-
-
Atlantico
-
Barranquilla, Atlantico, Colombia
- Novartis Investigative Site
-
-
Bolivar
-
Cartagena, Bolivar, Colombia
- Novartis Investigative Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia, 0000
- Novartis Investigative Site
-
-
Santander
-
Bucaramanga, Santander, Colombia
- Novartis Investigative Site
-
Floridablanca, Santander, Colombia, 57-7
- Novartis Investigative Site
-
-
-
-
-
Beroun, Czech Republic, 266 01
- Novartis Investigative Site
-
Brandys nad Labem, Czech Republic, 250 01
- Novartis Investigative Site
-
Horovice, Czech Republic, 268 01
- Novartis Investigative Site
-
Jablonec nad Nisou, Czech Republic, 466 01
- Novartis Investigative Site
-
Karlovy Vary, Czech Republic, 360 09
- Novartis Investigative Site
-
Kladno, Czech Republic, 272 80
- Novartis Investigative Site
-
Klatovy, Czech Republic, 339 01
- Novartis Investigative Site
-
Kolin, Czech Republic, 280 20
- Novartis Investigative Site
-
Liberec V Kristianova, Czech Republic, 460 05
- Novartis Investigative Site
-
Melnik, Czech Republic, 276 01
- Novartis Investigative Site
-
Olomouc, Czech Republic, 779 00
- Novartis Investigative Site
-
Plzen, Czech Republic, 301 00
- Novartis Investigative Site
-
Prague 1, Czech Republic, 110 00
- Novartis Investigative Site
-
Prague 10, Vrsovice, Czech Republic, 10100
- Novartis Investigative Site
-
Prague 5, Czech Republic, 150 30
- Novartis Investigative Site
-
Praha 2, Czech Republic, 128 08
- Novartis Investigative Site
-
Praha 4, Czech Republic, 142 00
- Novartis Investigative Site
-
Semily, Czech Republic, 513 31
- Novartis Investigative Site
-
Strakonice, Czech Republic, 38601
- Novartis Investigative Site
-
Trebic, Czech Republic, 674 01
- Novartis Investigative Site
-
Uherske Hradiste, Czech Republic, 686 01
- Novartis Investigative Site
-
Uherske Hradiste, Czech Republic, 68601
- Novartis Investigative Site
-
Usti nad Labem, Czech Republic, 400 01
- Novartis Investigative Site
-
-
CZE
-
Bilovec, CZE, Czech Republic, 743 01
- Novartis Investigative Site
-
Praha 2, CZE, Czech Republic, 128 08
- Novartis Investigative Site
-
-
-
-
-
Aarhus C, Denmark, DK-8000
- Novartis Investigative Site
-
Copenhagen, Denmark, DK-2100
- Novartis Investigative Site
-
Esbjerg, Denmark, DK-6700
- Novartis Investigative Site
-
Hellerup, Denmark, DK-2900
- Novartis Investigative Site
-
Herning, Denmark, DK-7400
- Novartis Investigative Site
-
Randers NØ, Denmark, DK-8930
- Novartis Investigative Site
-
Roskilde, Denmark, DK-4000
- Novartis Investigative Site
-
Svendborg, Denmark, DK-5700
- Novartis Investigative Site
-
Vejle, Denmark, DK-7100
- Novartis Investigative Site
-
Viborg, Denmark, DK-8800
- Novartis Investigative Site
-
-
-
-
-
Santo Domingo, Dominican Republic
- Novartis Investigative Site
-
-
Republica Dominicana
-
Santo Domingo, Republica Dominicana, Dominican Republic
- Novartis Investigative Site
-
-
-
-
Guayas
-
Guayaquil, Guayas, Ecuador, 412
- Novartis Investigative Site
-
Guayaquil, Guayas, Ecuador
- Novartis Investigative Site
-
Guayaquil, Guayas, Ecuador, 559
- Novartis Investigative Site
-
-
Pichincha
-
Quito, Pichincha, Ecuador, 1701
- Novartis Investigative Site
-
-
-
-
-
Haabneeme, Viimsi vald, Estonia, 74001
- Novartis Investigative Site
-
Tallinn, Estonia, 13419
- Novartis Investigative Site
-
Tallinn, Estonia, 10138
- Novartis Investigative Site
-
Tartu, Estonia, 50410
- Novartis Investigative Site
-
-
-
-
-
HUS, Finland, 00029
- Novartis Investigative Site
-
Kemi, Finland, FIN-94100
- Novartis Investigative Site
-
Kuopio, Finland, 70100
- Novartis Investigative Site
-
Oulu, Finland, 90100
- Novartis Investigative Site
-
Tampere, Finland, 33521
- Novartis Investigative Site
-
-
-
-
-
Abbeville, France, 80100
- Novartis Investigative Site
-
Bayonne, France, 64100
- Novartis Investigative Site
-
Bayonne, France, 64109
- Novartis Investigative Site
-
Beziers Cedex, France, 34525
- Novartis Investigative Site
-
Bordeaux Cedex, France, 33075
- Novartis Investigative Site
-
Caen, France, 14000
- Novartis Investigative Site
-
Cholet, France, 49325
- Novartis Investigative Site
-
Creteil, France, 94010
- Novartis Investigative Site
-
Essey Les Nancy, France, 54270
- Novartis Investigative Site
-
Grenoble, France, 38043
- Novartis Investigative Site
-
Lagny sur Marne, France, 77405
- Novartis Investigative Site
-
Langres, France, 52206
- Novartis Investigative Site
-
Le Chesnay, France
- Novartis Investigative Site
-
Le Plessis Robinson, France, 92350
- Novartis Investigative Site
-
Limoges, France, 87001
- Novartis Investigative Site
-
Lomme, France, 59462
- Novartis Investigative Site
-
Montpellier, France, 34195
- Novartis Investigative Site
-
Nice Cedex 1, France, 06602
- Novartis Investigative Site
-
Paris, France, 75015
- Novartis Investigative Site
-
Paris cedex 10, France, 75010
- Novartis Investigative Site
-
Reims, France, 51092
- Novartis Investigative Site
-
Rouen, France, 76031
- Novartis Investigative Site
-
St Aubin Lès Elbeuf, France, 76410
- Novartis Investigative Site
-
Toulouse Cedex, France, 31059
- Novartis Investigative Site
-
Tourcoing, France, 59208
- Novartis Investigative Site
-
Valencienne, France, 59322
- Novartis Investigative Site
-
Vandoeuvre les Nancy, France, 54511
- Novartis Investigative Site
-
-
Cedex
-
Strasbourg, Cedex, France, 67091
- Novartis Investigative Site
-
-
-
-
-
Ahrensfelde, Germany, 16356
- Novartis Investigative Site
-
Bad Homburg, Germany, 61348
- Novartis Investigative Site
-
Bad Krozingen, Germany, 79189
- Novartis Investigative Site
-
Bad Salzuflen, Germany, 32105
- Novartis Investigative Site
-
Bad Schwartau, Germany, 23611
- Novartis Investigative Site
-
Barsinghausen, Germany, 30890
- Novartis Investigative Site
-
Berlin, Germany, 10117
- Novartis Investigative Site
-
Berlin, Germany, 14050
- Novartis Investigative Site
-
Berlin, Germany, 10787
- Novartis Investigative Site
-
Berlin, Germany, 10789
- Novartis Investigative Site
-
Berlin, Germany, 13347
- Novartis Investigative Site
-
Berlin, Germany, 10369
- Novartis Investigative Site
-
Berlin, Germany, 10115
- Novartis Investigative Site
-
Berlin, Germany, 13055
- Novartis Investigative Site
-
Berlin, Germany, 13509
- Novartis Investigative Site
-
Berlin, Germany, 10559
- Novartis Investigative Site
-
Berlin-Buch, Germany, 13125
- Novartis Investigative Site
-
Bernau, Germany, 16321
- Novartis Investigative Site
-
Bitburg, Germany, 54634
- Novartis Investigative Site
-
Bremen, Germany, 28277
- Novartis Investigative Site
-
Chemnitz, Germany, 09130
- Novartis Investigative Site
-
Darmstadt, Germany, 64287
- Novartis Investigative Site
-
Dessau-Roßlau, Germany, 06846
- Novartis Investigative Site
-
Dietzenbach, Germany, 63128
- Novartis Investigative Site
-
Dortmund, Germany, 44137
- Novartis Investigative Site
-
Dresden, Germany, 01309
- Novartis Investigative Site
-
Dresden, Germany, 01127
- Novartis Investigative Site
-
Dresden, Germany, 01129
- Novartis Investigative Site
-
Dresden, Germany, 01099
- Novartis Investigative Site
-
Eilenburg, Germany, 04838
- Novartis Investigative Site
-
Elsterwerda, Germany, 04910
- Novartis Investigative Site
-
Erfurt, Germany, 99084
- Novartis Investigative Site
-
Frankfurt, Germany, 65929
- Novartis Investigative Site
-
Frankfurt, Germany, 60488
- Novartis Investigative Site
-
Georgsmarienhütte, Germany, 49124
- Novartis Investigative Site
-
Giengen, Germany, 89537
- Novartis Investigative Site
-
Goch, Germany, 47574
- Novartis Investigative Site
-
Graben-Neudorf, Germany, 76676
- Novartis Investigative Site
-
Hamburg, Germany, 21075
- Novartis Investigative Site
-
Hamburg, Germany, 22041
- Novartis Investigative Site
-
Hamburg, Germany, 22291
- Novartis Investigative Site
-
Hamburg, Germany, 22765
- Novartis Investigative Site
-
Hamburg, Germany, 22527
- Novartis Investigative Site
-
Hamminkeln, Germany, 46499
- Novartis Investigative Site
-
Hannover, Germany, 30165
- Novartis Investigative Site
-
Heidelberg, Germany, 69115
- Novartis Investigative Site
-
Homburg, Germany, 66421
- Novartis Investigative Site
-
Hoppegarten-Dahlwitz, Germany, 15366
- Novartis Investigative Site
-
Huy / OT Anderbeck, Germany, 38836
- Novartis Investigative Site
-
Ingelheim, Germany, 55218
- Novartis Investigative Site
-
Jena, Germany, 07740
- Novartis Investigative Site
-
Jena, Germany, 07743
- Novartis Investigative Site
-
Kallstadt, Germany, 67169
- Novartis Investigative Site
-
Kassel, Germany, 34121
- Novartis Investigative Site
-
Kassel, Germany, 34125
- Novartis Investigative Site
-
Kassel, Germany, 34127
- Novartis Investigative Site
-
Kelkheim, Germany, 65779
- Novartis Investigative Site
-
Koethen, Germany, 06366
- Novartis Investigative Site
-
Künzelsau, Germany, 74653
- Novartis Investigative Site
-
Langen, Germany, 63225
- Novartis Investigative Site
-
Leipzig, Germany, 04357
- Novartis Investigative Site
-
Leipzig, Germany, 04103
- Novartis Investigative Site
-
Leipzig, Germany, 04109
- Novartis Investigative Site
-
Leipzig, Germany, 04129
- Novartis Investigative Site
-
Leipzig, Germany, 04315
- Novartis Investigative Site
-
Loehne, Germany, 32584
- Novartis Investigative Site
-
Ludwigshafen, Germany, 67067
- Novartis Investigative Site
-
Ludwigshafen, Germany, 67061
- Novartis Investigative Site
-
Lübeck, Germany, 23558
- Novartis Investigative Site
-
Lütjenburg, Germany, 24321
- Novartis Investigative Site
-
Mainz, Germany, 55131
- Novartis Investigative Site
-
Mainz, Germany, 55116
- Novartis Investigative Site
-
Mannheim, Germany, 68165
- Novartis Investigative Site
-
Meissen, Germany, 01662
- Novartis Investigative Site
-
Meißen, Germany, 01662
- Novartis Investigative Site
-
Muenster, Germany, 48149
- Novartis Investigative Site
-
Mönchengladbach, Germany, 41063
- Novartis Investigative Site
-
Mühldorf, Germany, 84453
- Novartis Investigative Site
-
Mühlheim, Germany, 45468
- Novartis Investigative Site
-
München, Germany, 80336
- Novartis Investigative Site
-
Münster, Germany, 48149
- Novartis Investigative Site
-
Neunkirchen, Germany, 66539
- Novartis Investigative Site
-
Neunkirchen, Germany, 57290
- Novartis Investigative Site
-
Nienburg, Germany, 31582
- Novartis Investigative Site
-
Offenbach, Germany, 63073
- Novartis Investigative Site
-
Oldenburg i.H., Germany, 23758
- Novartis Investigative Site
-
Osnabrück, Germany, 49080
- Novartis Investigative Site
-
Papenburg, Germany, 26871
- Novartis Investigative Site
-
Rhaunen, Germany, 55624
- Novartis Investigative Site
-
Riesa, Germany, 01589
- Novartis Investigative Site
-
Rodgau, Germany, 63110
- Novartis Investigative Site
-
Schenklengsfeld, Germany, 36277
- Novartis Investigative Site
-
Schkeuditz, Germany, 04435
- Novartis Investigative Site
-
Schwäbisch Hall, Germany, 74523
- Novartis Investigative Site
-
St. Ingbert - Oberwuerzbach, Germany, 66386
- Novartis Investigative Site
-
Unterschneidheim, Germany, 73485
- Novartis Investigative Site
-
Wangen, Germany, 88239
- Novartis Investigative Site
-
Wardenburg, Germany, 26203
- Novartis Investigative Site
-
Weeze, Germany, 47652
- Novartis Investigative Site
-
Wermsdorf, Germany, 04779
- Novartis Investigative Site
-
Westhofen, Germany, 67593
- Novartis Investigative Site
-
Wetzlar-Naunheim, Germany, 35584
- Novartis Investigative Site
-
Weyhe, Germany, 28844
- Novartis Investigative Site
-
Wolmirstedt, Germany, 39326
- Novartis Investigative Site
-
-
Baden-Württemberg
-
Mannheim, Baden-Württemberg, Germany, 68305
- Novartis Investigative Site
-
-
-
-
-
Guatemala City, Guatemala, 01010
- Novartis Investigative Site
-
Guatemala City, Guatemala, 01011
- Novartis Investigative Site
-
Guatemala City, Guatemala, 01015
- Novartis Investigative Site
-
-
-
-
-
Hong Kong, Hong Kong
- Novartis Investigative Site
-
Hong Kong, Hong Kong, HONG KONG
- Novartis Investigative Site
-
Hong Kong SAR, Hong Kong
- Novartis Investigative Site
-
-
-
-
-
Baja, Hungary, 6500
- Novartis Investigative Site
-
Balatonfured, Hungary, H-8231
- Novartis Investigative Site
-
Budapest, Hungary, 1125
- Novartis Investigative Site
-
Budapest, Hungary, 1145
- Novartis Investigative Site
-
Budapest, Hungary, 1085
- Novartis Investigative Site
-
Budapest, Hungary, 1134
- Novartis Investigative Site
-
Budapest, Hungary, 1027
- Novartis Investigative Site
-
Budapest, Hungary, 1122
- Novartis Investigative Site
-
Budapest, Hungary, H-1032
- Novartis Investigative Site
-
Budapest, Hungary, 1096
- Novartis Investigative Site
-
Budapest, Hungary, 1043
- Novartis Investigative Site
-
Budapest, Hungary, H-1096
- Novartis Investigative Site
-
Budapest, Hungary, 1021
- Novartis Investigative Site
-
Budapest, Hungary, H-1106
- Novartis Investigative Site
-
Cegled, Hungary, 2700
- Novartis Investigative Site
-
Debrecen, Hungary, 4032
- Novartis Investigative Site
-
Eger, Hungary, H-3300
- Novartis Investigative Site
-
Hodmezovasarhely, Hungary, 6800
- Novartis Investigative Site
-
Kaposvár, Hungary, 7400
- Novartis Investigative Site
-
Miskolc, Hungary, 3526
- Novartis Investigative Site
-
Nagykanizsa, Hungary, 8800
- Novartis Investigative Site
-
Nyiregyháza, Hungary, 4400
- Novartis Investigative Site
-
Pecs, Hungary, 7643
- Novartis Investigative Site
-
Sopron, Hungary, 9400
- Novartis Investigative Site
-
Szeged, Hungary, H-6720
- Novartis Investigative Site
-
Szekesfehervar, Hungary, 8000
- Novartis Investigative Site
-
Szekszard, Hungary, 7100
- Novartis Investigative Site
-
Zalaegerszeg, Hungary, 8900
- Novartis Investigative Site
-
-
Baranya
-
Pecs, Baranya, Hungary, 7621
- Novartis Investigative Site
-
-
-
-
-
Kopavogur, Iceland, 201
- Novartis Investigative Site
-
Reykjavik, Iceland, IS-109
- Novartis Investigative Site
-
Reykjavik, Iceland, IS-101
- Novartis Investigative Site
-
-
-
-
-
Ahmedabad, India, 380052
- Novartis Investigative Site
-
Hyderabad, India, 500 063
- Novartis Investigative Site
-
Indore, India, 452014
- Novartis Investigative Site
-
-
Andhra Pradesh
-
Guntur, Andhra Pradesh, India, 522001
- Novartis Investigative Site
-
Hyderabad, Andhra Pradesh, India, 500012
- Novartis Investigative Site
-
Hyderabad, Andhra Pradesh, India, 500082
- Novartis Investigative Site
-
Tirupati, Andhra Pradesh, India, 517501
- Novartis Investigative Site
-
Vishakhapatnam, Andhra Pradesh, India, 530002
- Novartis Investigative Site
-
Vishakhapatnam, Andhra Pradesh, India, 530 013
- Novartis Investigative Site
-
-
Andhra Pradesh, INDIA
-
Hyderabad, Andhra Pradesh, INDIA, India, 500034
- Novartis Investigative Site
-
-
Delhi
-
Dehli, Delhi, India, 110080
- Novartis Investigative Site
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380014
- Novartis Investigative Site
-
Ahmedabad, Gujarat, India, 380 013
- Novartis Investigative Site
-
Ahmedabad, Gujarat, India, 380025
- Novartis Investigative Site
-
Anand, Gujarat, India, 388325
- Novartis Investigative Site
-
Surat, Gujarat, India, 395001
- Novartis Investigative Site
-
-
Gujrat
-
Rajkot, Gujrat, India, 360001
- Novartis Investigative Site
-
Vadodara, Gujrat, India, 390015
- Novartis Investigative Site
-
-
Haryana
-
Gurgaon, Haryana, India, 122001
- Novartis Investigative Site
-
-
Karnataka
-
Bangalore, Karnataka, India, 560038
- Novartis Investigative Site
-
Bangalore, Karnataka, India, 560092
- Novartis Investigative Site
-
Banglaore, Karnataka, India, 560054
- Novartis Investigative Site
-
Mangalore, Karnataka, India, 575002
- Novartis Investigative Site
-
Mysore, Karnataka, India, 570004
- Novartis Investigative Site
-
-
Kerala
-
Cochin, Kerala, India, 683572
- Novartis Investigative Site
-
Trivandrum, Kerala, India, 695011
- Novartis Investigative Site
-
Trivandrum, Kerala, India, 695607
- Novartis Investigative Site
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400012
- Novartis Investigative Site
-
Nagpur, Maharashtra, India, 400012
- Novartis Investigative Site
-
Nagpur, Maharashtra, India, 440 010
- Novartis Investigative Site
-
Nagpur, Maharashtra, India, 44000033
- Novartis Investigative Site
-
Nashik, Maharashtra, India, 422005
- Novartis Investigative Site
-
Nashik, Maharashtra, India, 422 005
- Novartis Investigative Site
-
Nashik, Maharashtra, India, 422002
- Novartis Investigative Site
-
Pune, Maharashtra, India, 411 011
- Novartis Investigative Site
-
Pune, Maharashtra, India, 411011
- Novartis Investigative Site
-
Pune, Maharashtra, India, 411 005
- Novartis Investigative Site
-
-
Punjab
-
Ludhiana, Punjab, India, 141002
- Novartis Investigative Site
-
-
Rajasthan
-
Bikaner, Rajasthan, India, 334003
- Novartis Investigative Site
-
Jaipur, Rajasthan, India, 302016
- Novartis Investigative Site
-
Kota, Rajasthan, India, 324005
- Novartis Investigative Site
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, India, 600004
- Novartis Investigative Site
-
Chennai, Tamil Nadu, India, 600020
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, India, 226003
- Novartis Investigative Site
-
Varanasi, Uttar Pradesh, India, 221 005
- Novartis Investigative Site
-
-
-
-
-
Ashkelon, Israel, 78278
- Novartis Investigative Site
-
Hadera, Israel, 38100
- Novartis Investigative Site
-
Haifa, Israel, 31096
- Novartis Investigative Site
-
Haifa, Israel, 3436212
- Novartis Investigative Site
-
Jerusalem, Israel, 91031
- Novartis Investigative Site
-
Jerusalem, Israel, 9112001
- Novartis Investigative Site
-
Petach Tikva, Israel, 49100
- Novartis Investigative Site
-
Rehovot, Israel, 76100
- Novartis Investigative Site
-
Safed, Israel, 13100
- Novartis Investigative Site
-
-
-
-
AO
-
Aosta, AO, Italy, 11100
- Novartis Investigative Site
-
-
AR
-
Cortona, AR, Italy, 52044
- Novartis Investigative Site
-
-
BG
-
Bergamo, BG, Italy, 24128
- Novartis Investigative Site
-
Seriate, BG, Italy, 24068
- Novartis Investigative Site
-
Treviglio, BG, Italy, 24047
- Novartis Investigative Site
-
-
BR
-
San Pietro Vernotico, BR, Italy, 72027
- Novartis Investigative Site
-
-
BZ
-
Bolzano, BZ, Italy, 39100
- Novartis Investigative Site
-
-
CS
-
Cosenza, CS, Italy, 87100
- Novartis Investigative Site
-
-
CZ
-
Catanzaro, CZ, Italy, 88100
- Novartis Investigative Site
-
-
FE
-
Cona, FE, Italy, 44100
- Novartis Investigative Site
-
-
FI
-
Firenze, FI, Italy, 50143
- Novartis Investigative Site
-
-
GE
-
Genova, GE, Italy, 16132
- Novartis Investigative Site
-
-
IS
-
Pozzilli, IS, Italy, 86077
- Novartis Investigative Site
-
-
LU
-
Lido di Camaiore, LU, Italy, 55041
- Novartis Investigative Site
-
-
MB
-
Monza, MB, Italy, 20900
- Novartis Investigative Site
-
-
ME
-
Milazzo, ME, Italy, 98057
- Novartis Investigative Site
-
-
MI
-
Milano, MI, Italy, 20122
- Novartis Investigative Site
-
-
MO
-
Modena, MO, Italy, 41100
- Novartis Investigative Site
-
-
PD
-
Piove di Sacco, PD, Italy, 35028
- Novartis Investigative Site
-
-
PG
-
Perugia, PG, Italy, 06100
- Novartis Investigative Site
-
-
PI
-
Pisa, PI, Italy, 56126
- Novartis Investigative Site
-
-
PT
-
Pescia, PT, Italy, 51017
- Novartis Investigative Site
-
-
PV
-
Casorate Primo, PV, Italy, 27022
- Novartis Investigative Site
-
Pavia, PV, Italy, 27100
- Novartis Investigative Site
-
Stradella, PV, Italy, 27049
- Novartis Investigative Site
-
-
RM
-
Albano Laziale, RM, Italy, 00041
- Novartis Investigative Site
-
Roma, RM, Italy, 00163
- Novartis Investigative Site
-
-
SA
-
Battipaglia, SA, Italy, 84091
- Novartis Investigative Site
-
Cava De' Tirreni, SA, Italy, 84013
- Novartis Investigative Site
-
Salerno, SA, Italy, 84131
- Novartis Investigative Site
-
-
SS
-
Sassari, SS, Italy, 07100
- Novartis Investigative Site
-
Thiesi, SS, Italy, 07047
- Novartis Investigative Site
-
-
UD
-
Palmanova, UD, Italy, 33057
- Novartis Investigative Site
-
San Daniele Del Friuli, UD, Italy, 33038
- Novartis Investigative Site
-
-
VA
-
Tradate, VA, Italy, 21049
- Novartis Investigative Site
-
Varese, VA, Italy, 21100
- Novartis Investigative Site
-
-
VV
-
Vibo Valentia, VV, Italy, 89900
- Novartis Investigative Site
-
-
-
-
-
Busan, Korea, Republic of, 602-739
- Novartis Investigative Site
-
Daegu, Korea, Republic of, 705-703
- Novartis Investigative Site
-
Daegu, Korea, Republic of, 705-718
- Novartis Investigative Site
-
Gwangju, Korea, Republic of, 501-757
- Novartis Investigative Site
-
Pusan, Korea, Republic of, 614-735
- Novartis Investigative Site
-
Seoul, Korea, Republic of, 156-707
- Novartis Investigative Site
-
Seoul, Korea, Republic of, 110-102
- Novartis Investigative Site
-
Seoul, Korea, Republic of, 134-701
- Novartis Investigative Site
-
-
Gangwon-Do
-
Wonju, Gangwon-Do, Korea, Republic of, 220-701
- Novartis Investigative Site
-
-
Gyeonggi-do
-
Suwon, Gyeonggi-do, Korea, Republic of, 443-380
- Novartis Investigative Site
-
-
Korea
-
Seoul, Korea, Korea, Republic of, 137-701
- Novartis Investigative Site
-
Seoul, Korea, Korea, Republic of, 120-752
- Novartis Investigative Site
-
Seoul, Korea, Korea, Republic of, 138-736
- Novartis Investigative Site
-
-
-
-
-
Daugavplis, Latvia, LV-5417
- Novartis Investigative Site
-
Kuldiga, Latvia, LV-3300
- Novartis Investigative Site
-
Preili, Latvia, LV-5301
- Novartis Investigative Site
-
Riga, Latvia, 1002
- Novartis Investigative Site
-
Ventspils, Latvia, LV-3601
- Novartis Investigative Site
-
-
LV
-
Liepaja, LV, Latvia, LV-3414
- Novartis Investigative Site
-
-
-
-
-
Kaunas, Lithuania, LT-49387
- Novartis Investigative Site
-
Kaunas, Lithuania, 50009
- Novartis Investigative Site
-
Kedainiai, Lithuania, LT-57164
- Novartis Investigative Site
-
Siauliai, Lithuania, LT-76231
- Novartis Investigative Site
-
Vilnius, Lithuania, LT-08661
- Novartis Investigative Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Novartis Investigative Site
-
Kuala Lumpur, Malaysia, 50400
- Novartis Investigative Site
-
-
Penang
-
Pulau Pinang, Penang, Malaysia, 10990
- Novartis Investigative Site
-
-
Sarawak
-
Kuching, Sarawak, Malaysia, 94300
- Novartis Investigative Site
-
-
-
-
-
Aguascalientes, Mexico, 20230
- Novartis Investigative Site
-
Queretaro, Mexico, 76000
- Novartis Investigative Site
-
San Luis Potosi, Mexico, 78200
- Novartis Investigative Site
-
San Luis Potosí, Mexico, 78200
- Novartis Investigative Site
-
San Luis Potosí, Mexico, 78240
- Novartis Investigative Site
-
-
Distrito Federal
-
Mexico, Distrito Federal, Mexico, 07300
- Novartis Investigative Site
-
Mexico City, Distrito Federal, Mexico, 06700
- Novartis Investigative Site
-
Mexico D.F, Distrito Federal, Mexico, 03100
- Novartis Investigative Site
-
México, Distrito Federal, Mexico, 06720
- Novartis Investigative Site
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44280
- Novartis Investigative Site
-
Zapopan, Jalisco, Mexico, 45200
- Novartis Investigative Site
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64710
- Novartis Investigative Site
-
-
Queretaro
-
San Juan del Rio, Queretaro, Mexico, 76800
- Novartis Investigative Site
-
-
-
-
-
Amersfoort, Netherlands, 3813 TZ
- Novartis Investigative Site
-
Arnhem, Netherlands, 6815 AD
- Novartis Investigative Site
-
Blaricum, Netherlands, 1261 AN
- Novartis Investigative Site
-
Breda, Netherlands, 4818 CK
- Novartis Investigative Site
-
Delft, Netherlands, 2625 AD
- Novartis Investigative Site
-
Den Bosch, Netherlands, 5223 GZ
- Novartis Investigative Site
-
Den Haag, Netherlands, 2512 VA
- Novartis Investigative Site
-
Ede, Netherlands, 6716 RP
- Novartis Investigative Site
-
Eindhoven, Netherlands, 5623 EJ
- Novartis Investigative Site
-
Goes, Netherlands, 4462 RA
- Novartis Investigative Site
-
Gorinchem, Netherlands, 4204 AA
- Novartis Investigative Site
-
Hardenberg, Netherlands, 7770 AA
- Novartis Investigative Site
-
Harderwijk, Netherlands, 3840 AC
- Novartis Investigative Site
-
Heerenveen, Netherlands, 8441 PW
- Novartis Investigative Site
-
Hengelo, Netherlands, 7555 DL
- Novartis Investigative Site
-
Hoorn, Netherlands, 1625 HV
- Novartis Investigative Site
-
Maastricht, Netherlands, 6229 HX
- Novartis Investigative Site
-
Nijmegen, Netherlands, 6525 GA
- Novartis Investigative Site
-
Sneek, Netherlands, 8601 ZK
- Novartis Investigative Site
-
Tilburg, Netherlands, 5022 GC
- Novartis Investigative Site
-
Veldhoven, Netherlands, 5504 DB
- Novartis Investigative Site
-
-
NL
-
Oss, NL, Netherlands, 5342 BT
- Novartis Investigative Site
-
-
-
-
Panamá
-
Panama City, Panamá, Panama
- Novartis Investigative Site
-
Panama City, Panamá, Panama, 0831-02351
- Novartis Investigative Site
-
-
-
-
-
Arequipa, Peru, Areq01
- Novartis Investigative Site
-
-
Lima
-
Bellavista, Lima, Peru, CALLAO 02
- Novartis Investigative Site
-
Cercado de Lima, Lima, Peru, 01
- Novartis Investigative Site
-
Jesus Maria, Lima, Peru, 11
- Novartis Investigative Site
-
La Molina, Lima, Peru, 12
- Novartis Investigative Site
-
San Borja, Lima, Peru, 41
- Novartis Investigative Site
-
San Isidro, Lima, Peru, 27
- Novartis Investigative Site
-
San Miguel, Lima, Peru, 32
- Novartis Investigative Site
-
-
-
-
-
Bulacan, Philippines, 3020
- Novartis Investigative Site
-
Manila, Philippines
- Novartis Investigative Site
-
Manila, Philippines, 1000
- Novartis Investigative Site
-
Manila, Philippines, 1003
- Novartis Investigative Site
-
Pasig City, Philippines, 1605
- Novartis Investigative Site
-
Quezon City, Philippines, 1102
- Novartis Investigative Site
-
Quezon City, Philippines, 1100
- Novartis Investigative Site
-
San Juan City, Philippines, 1500
- Novartis Investigative Site
-
-
Batangas
-
Lipa City, Batangas, Philippines, 4217
- Novartis Investigative Site
-
-
Manila
-
Quezon City, Manila, Philippines, 1100
- Novartis Investigative Site
-
-
Metro Manila
-
Quezon City, Metro Manila, Philippines, 1109
- Novartis Investigative Site
-
-
-
-
-
Bialystok, Poland, 15-875
- Novartis Investigative Site
-
Gdynia, Poland, 81-157
- Novartis Investigative Site
-
Gdynia, Poland, 81-472
- Novartis Investigative Site
-
Gdynia, Poland, 81-548
- Novartis Investigative Site
-
Gdynia, Poland, 81-519
- Novartis Investigative Site
-
Gliwice, Poland, 44-100
- Novartis Investigative Site
-
Golub-Dobrzyn, Poland, 87-400
- Novartis Investigative Site
-
Katowice, Poland, 40-084
- Novartis Investigative Site
-
Katowice, Poland, 40-645
- Novartis Investigative Site
-
Katowice, Poland, 40-530
- Novartis Investigative Site
-
Krakow, Poland, 30-082
- Novartis Investigative Site
-
Krakow, Poland, 30-015
- Novartis Investigative Site
-
Kutno, Poland, 99-300
- Novartis Investigative Site
-
Lodz, Poland, 91-302
- Novartis Investigative Site
-
Lublin, Poland, 20-857
- Novartis Investigative Site
-
Olawa, Poland, 55-200
- Novartis Investigative Site
-
Skierniewice, Poland, 96-100
- Novartis Investigative Site
-
Wroclaw, Poland, 52-612
- Novartis Investigative Site
-
Wroclaw, Poland, 50-088
- Novartis Investigative Site
-
Wroclaw, Poland, 51-312
- Novartis Investigative Site
-
Zabrze, Poland, 41-800
- Novartis Investigative Site
-
-
-
-
-
Amadora, Portugal, 2720-276
- Novartis Investigative Site
-
Covilha, Portugal, 6200-251
- Novartis Investigative Site
-
Guimarães, Portugal, 4835-044
- Novartis Investigative Site
-
Lisboa, Portugal, 1169-024
- Novartis Investigative Site
-
Lisboa, Portugal, 1449-005
- Novartis Investigative Site
-
Penafiel, Portugal, 4564-007
- Novartis Investigative Site
-
Portalegre, Portugal, 7300-853
- Novartis Investigative Site
-
Porto, Portugal, 4200-319
- Novartis Investigative Site
-
Setubal, Portugal, 2910-446
- Novartis Investigative Site
-
-
Portuigal
-
Vila Real, Portuigal, Portugal, 5000-508
- Novartis Investigative Site
-
-
-
-
-
Arad, Romania, 310158
- Novartis Investigative Site
-
Bucharest, Romania, 050098
- Novartis Investigative Site
-
Bucharest, Romania, 060011
- Novartis Investigative Site
-
Bucharest, Romania, 050659
- Novartis Investigative Site
-
Bucharest, Romania, 020054
- Novartis Investigative Site
-
Bucuresti, Romania, 062272
- Novartis Investigative Site
-
Bucuresti, Romania, 011728
- Novartis Investigative Site
-
Deva, Romania, 330084
- Novartis Investigative Site
-
Pitesti, Romania, 110114
- Novartis Investigative Site
-
Timisoara, Romania, 300736
- Novartis Investigative Site
-
Timisoara, Romania, 300041
- Novartis Investigative Site
-
Timisoara, Romania, 300310
- Novartis Investigative Site
-
Timisoara, Romania, 300020
- Novartis Investigative Site
-
Timisoara, Romania, 300361
- Novartis Investigative Site
-
-
District 1
-
Bucharest, District 1, Romania
- Novartis Investigative Site
-
Bucuresti, District 1, Romania, 014461
- Novartis Investigative Site
-
-
District 2
-
Bucuresti, District 2, Romania, 021345
- Novartis Investigative Site
-
-
District 5
-
Bucharest, District 5, Romania, 050538
- Novartis Investigative Site
-
-
Jud. Dolj
-
Craiova, Jud. Dolj, Romania, 200147
- Novartis Investigative Site
-
-
Jud.Dolj
-
Craiova, Jud.Dolj, Romania, 200235
- Novartis Investigative Site
-
-
Jud.Prahova
-
Ploiesti, Jud.Prahova, Romania, 100410
- Novartis Investigative Site
-
-
jud. Timis
-
Timisoara, jud. Timis, Romania, 300359
- Novartis Investigative Site
-
-
-
-
-
Ekaterinburg, Russian Federation, 620028
- Novartis Investigative Site
-
Ekaterinburg, Russian Federation, 620102
- Novartis Investigative Site
-
Ekaterinburg, Russian Federation, 620137
- Novartis Investigative Site
-
Gatchina, Russian Federation, 188300
- Novartis Investigative Site
-
Ivanovo, Russian Federation, 153012
- Novartis Investigative Site
-
Izhevsk, Russian Federation, 426063
- Novartis Investigative Site
-
Kazan, Russian Federation, 420012
- Novartis Investigative Site
-
Kemerovo, Russian Federation, 650002
- Novartis Investigative Site
-
Kemerovo, Russian Federation, 650029
- Novartis Investigative Site
-
Kemerovo, Russian Federation, 650099
- Novartis Investigative Site
-
Kirov, Russian Federation, 610027
- Novartis Investigative Site
-
Krasnodar, Russian Federation, 350086
- Novartis Investigative Site
-
Krasnodar, Russian Federation, 350012
- Novartis Investigative Site
-
Moscow, Russian Federation, 125284
- Novartis Investigative Site
-
Moscow, Russian Federation, 117198
- Novartis Investigative Site
-
Moscow, Russian Federation, 105229
- Novartis Investigative Site
-
Moscow, Russian Federation, 119333
- Novartis Investigative Site
-
Moscow, Russian Federation, 119992
- Novartis Investigative Site
-
Moscow, Russian Federation, 127473
- Novartis Investigative Site
-
Moscow, Russian Federation, 115516
- Novartis Investigative Site
-
Moscow, Russian Federation, 121552
- Novartis Investigative Site
-
Moscow, Russian Federation, 117556
- Novartis Investigative Site
-
Moscow, Russian Federation, 121309
- Novartis Investigative Site
-
Moscow, Russian Federation, 101990
- Novartis Investigative Site
-
Moscow, Russian Federation, 115280
- Novartis Investigative Site
-
Moscow, Russian Federation, 119881
- Novartis Investigative Site
-
Moscow, Russian Federation, 111539
- Novartis Investigative Site
-
Moscow, Russian Federation, 109240
- Novartis Investigative Site
-
Moscow, Russian Federation, 105203
- Novartis Investigative Site
-
Moscow, Russian Federation, 115487
- Novartis Investigative Site
-
N. Novgorod, Russian Federation, 603003
- Novartis Investigative Site
-
N.Novgorod, Russian Federation, 603005
- Novartis Investigative Site
-
N.Novgorod, Russian Federation, 603073
- Novartis Investigative Site
-
Nizhnii Novgorod, Russian Federation, 603126
- Novartis Investigative Site
-
Novosibirsk, Russian Federation, 630087
- Novartis Investigative Site
-
Novosibirsk, Russian Federation, 630051
- Novartis Investigative Site
-
Novosibirsk-117, Russian Federation, 630117
- Novartis Investigative Site
-
Orenburg, Russian Federation, 460000
- Novartis Investigative Site
-
Orenburg, Russian Federation, 460040
- Novartis Investigative Site
-
Penza, Russian Federation, 440026
- Novartis Investigative Site
-
Perm, Russian Federation, 614097
- Novartis Investigative Site
-
Petrozavodsk, Russian Federation, 185019
- Novartis Investigative Site
-
Rostov-on-Don, Russian Federation, 344022
- Novartis Investigative Site
-
S-Petersburg, Russian Federation, 191144
- Novartis Investigative Site
-
S.-Petersburg, Russian Federation, 198205
- Novartis Investigative Site
-
S.-Petersburg, Russian Federation, 194354
- Novartis Investigative Site
-
Saint Petersburg, Russian Federation, 199106
- Novartis Investigative Site
-
Saint Petersburg, Russian Federation, 195067
- Novartis Investigative Site
-
Saint-Petersburg, Russian Federation, 194044
- Novartis Investigative Site
-
Saint-Petersburg, Russian Federation, 197341
- Novartis Investigative Site
-
Samara, Russian Federation, 443070
- Novartis Investigative Site
-
Samara, Russian Federation, 443095
- Novartis Investigative Site
-
Sankt-Peterburg, Russian Federation, 197022
- Novartis Investigative Site
-
Saratov, Russian Federation, 410028
- Novartis Investigative Site
-
Saratov, Russian Federation, 410012
- Novartis Investigative Site
-
Smolensk, Russian Federation, 214018
- Novartis Investigative Site
-
St-Peterburg, Russian Federation, 190000
- Novartis Investigative Site
-
St-Petersburg, Russian Federation, 194017
- Novartis Investigative Site
-
St-Petersburg, Russian Federation, 194295
- Novartis Investigative Site
-
St-Petersburg, Russian Federation, 196084
- Novartis Investigative Site
-
St-Petersburg, Russian Federation, 197119
- Novartis Investigative Site
-
St. Petersburg, Russian Federation, 198013
- Novartis Investigative Site
-
St.Petersburg, Russian Federation, 193163
- Novartis Investigative Site
-
Syktyvkar, Russian Federation, 167981
- Novartis Investigative Site
-
Tula, Russian Federation, 300053
- Novartis Investigative Site
-
Tver, Russian Federation, 170036
- Novartis Investigative Site
-
Vladimir, Russian Federation, 600020
- Novartis Investigative Site
-
Volgograd, Russian Federation, 400008
- Novartis Investigative Site
-
Voronezh, Russian Federation, 394065
- Novartis Investigative Site
-
Yaroslavl, Russian Federation, 150003
- Novartis Investigative Site
-
Yaroslavl, Russian Federation, 150062
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapore, 119074
- Novartis Investigative Site
-
Singapore, Singapore, 308433
- Novartis Investigative Site
-
Singapore, Singapore, 169609
- Novartis Investigative Site
-
Singapore, Singapore, 768825
- Novartis Investigative Site
-
-
-
-
-
Bratislava, Slovakia, 821 07
- Novartis Investigative Site
-
Bratislava, Slovakia, 851 07
- Novartis Investigative Site
-
Bratislava, Slovakia, 81369
- Novartis Investigative Site
-
Bratislava, Slovakia, 841 04
- Novartis Investigative Site
-
Dolny Kubin, Slovakia, 026 01
- Novartis Investigative Site
-
Dunajska Streda, Slovakia, 929 01
- Novartis Investigative Site
-
Kosice, Slovakia, 040 01
- Novartis Investigative Site
-
Kosice, Slovakia, 04001
- Novartis Investigative Site
-
Kralovsky Chlmec, Slovakia, 077 01
- Novartis Investigative Site
-
Levice, Slovakia, 934 01
- Novartis Investigative Site
-
Levice, Slovakia, 934 05
- Novartis Investigative Site
-
Lucenec, Slovakia, 984 01
- Novartis Investigative Site
-
Martin, Slovakia, 036 01
- Novartis Investigative Site
-
Nitra, Slovakia, 949 88
- Novartis Investigative Site
-
Trnava, Slovakia, 91701
- Novartis Investigative Site
-
Trnava, Slovakia, 917 01
- Novartis Investigative Site
-
-
Slovak Republic
-
Bratislava, Slovak Republic, Slovakia, 841 04
- Novartis Investigative Site
-
Brezno, Slovak Republic, Slovakia, 977 42
- Novartis Investigative Site
-
Kosice, Slovak Republic, Slovakia, 040 22
- Novartis Investigative Site
-
Levice, Slovak Republic, Slovakia, 93401
- Novartis Investigative Site
-
Presov, Slovak Republic, Slovakia, 08001
- Novartis Investigative Site
-
Presov, Slovak Republic, Slovakia, 080 01
- Novartis Investigative Site
-
Svidnik, Slovak Republic, Slovakia, 08901
- Novartis Investigative Site
-
Vranov nad Toplou, Slovak Republic, Slovakia, 09301
- Novartis Investigative Site
-
-
-
-
-
Alberton, South Africa, 1449
- Novartis Investigative Site
-
Bloemfontein, South Africa, 9301
- Novartis Investigative Site
-
Bloemfontein, South Africa, 9317
- Novartis Investigative Site
-
Breyton, South Africa, 2330
- Novartis Investigative Site
-
Brits, South Africa, 250
- Novartis Investigative Site
-
Cape Town, South Africa, 7500
- Novartis Investigative Site
-
Cape Town, South Africa, 7531
- Novartis Investigative Site
-
Cape Town, South Africa, 7505
- Novartis Investigative Site
-
Cape Town, South Africa, 7405
- Novartis Investigative Site
-
Cape Town, South Africa
- Novartis Investigative Site
-
Durban, South Africa, 4001
- Novartis Investigative Site
-
Durban, South Africa, 4110
- Novartis Investigative Site
-
Durban, South Africa, 4052
- Novartis Investigative Site
-
East London, South Africa
- Novartis Investigative Site
-
Gatesville, South Africa, 7764
- Novartis Investigative Site
-
Johannesburg, South Africa, 2193
- Novartis Investigative Site
-
Kempton Park, South Africa, 1620
- Novartis Investigative Site
-
Port Elizabeth, South Africa, 6014
- Novartis Investigative Site
-
Pretoria, South Africa, 0184
- Novartis Investigative Site
-
Pretoria, South Africa
- Novartis Investigative Site
-
Pretoria, South Africa, 0121
- Novartis Investigative Site
-
Umkomaas, South Africa, 4170
- Novartis Investigative Site
-
Witbank, South Africa
- Novartis Investigative Site
-
Worcester, South Africa, 6850
- Novartis Investigative Site
-
-
Eastern Cape
-
Mthatha, Eastern Cape, South Africa
- Novartis Investigative Site
-
-
Free State
-
Bloemfontein, Free State, South Africa, 9301
- Novartis Investigative Site
-
-
Gauteng
-
Soweto, Gauteng, South Africa, 2013
- Novartis Investigative Site
-
-
Mpumalanga
-
Middelburg, Mpumalanga, South Africa, 1050
- Novartis Investigative Site
-
-
Western Cape
-
Paarl, Western Cape, South Africa, 7626
- Novartis Investigative Site
-
Somerset West, Western Cape, South Africa, 7130
- Novartis Investigative Site
-
-
-
-
-
Madrid, Spain, 28007
- Novartis Investigative Site
-
-
Andalucia
-
Almeria, Andalucia, Spain, 04120
- Novartis Investigative Site
-
Malaga, Andalucia, Spain, 29010
- Novartis Investigative Site
-
Marbella, Andalucia, Spain, 29600
- Novartis Investigative Site
-
Sevilla, Andalucia, Spain, 41017
- Novartis Investigative Site
-
Sevilla, Andalucia, Spain, 41014
- Novartis Investigative Site
-
-
Cataluna
-
Sant Joan Despi, Cataluna, Spain, 08970
- Novartis Investigative Site
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08035
- Novartis Investigative Site
-
Barcelona, Catalunya, Spain, 08003
- Novartis Investigative Site
-
-
Comunidad Valenciana
-
Alicante, Comunidad Valenciana, Spain, 03004
- Novartis Investigative Site
-
Valencia, Comunidad Valenciana, Spain, 46010
- Novartis Investigative Site
-
Valencia, Comunidad Valenciana, Spain, 46015
- Novartis Investigative Site
-
-
Extremadura
-
Mérida, Extremadura, Spain, 06800
- Novartis Investigative Site
-
-
Galicia
-
A Coruna, Galicia, Spain, 15006
- Novartis Investigative Site
-
Ferrol, Galicia, Spain, 15405
- Novartis Investigative Site
-
La Coruna, Galicia, Spain, 15006
- Novartis Investigative Site
-
Santiago de Compostela, Galicia, Spain, 15706
- Novartis Investigative Site
-
Vigo, Galicia, Spain, 36211
- Novartis Investigative Site
-
-
Islas Baleares
-
Mallorca, Islas Baleares, Spain, 07198
- Novartis Investigative Site
-
-
Madrid
-
Alcala de Henares, Madrid, Spain, 28805
- Novartis Investigative Site
-
Majadahonda, Madrid, Spain, 28222
- Novartis Investigative Site
-
Mostoles, Madrid, Spain, 28935
- Novartis Investigative Site
-
-
Murcia
-
El Palmar, Murcia, Spain, 30120
- Novartis Investigative Site
-
-
-
-
-
Göteborg, Sweden, 416 85
- Novartis Investigative Site
-
Göteborg, Sweden
- Novartis Investigative Site
-
Helsingborg, Sweden, 25232
- Novartis Investigative Site
-
Härnösand, Sweden, 871 82
- Novartis Investigative Site
-
Karlshamn, Sweden, 37480
- Novartis Investigative Site
-
Lund, Sweden, 221 85
- Novartis Investigative Site
-
Motala, Sweden, 59185
- Novartis Investigative Site
-
Stockholm, Sweden, 141 86
- Novartis Investigative Site
-
Vällingby, Sweden, 162 68
- Novartis Investigative Site
-
-
-
-
-
Changhua, Taiwan, 500
- Novartis Investigative Site
-
Ilan, Taiwan
- Novartis Investigative Site
-
Kaohsiung, Taiwan, 82445
- Novartis Investigative Site
-
Taichung, Taiwan, 40447
- Novartis Investigative Site
-
Taipei, Taiwan, 10002
- Novartis Investigative Site
-
Taipei, Taiwan, 114
- Novartis Investigative Site
-
-
Taiwan ROC
-
Tainan 704, Taiwan ROC, Taiwan
- Novartis Investigative Site
-
-
Taiwan, ROC
-
Taipei, Taiwan, ROC, Taiwan, 112
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thailand, 10400
- Novartis Investigative Site
-
Khon Kaen, Thailand, 40002
- Novartis Investigative Site
-
Muang, Thailand, 65000
- Novartis Investigative Site
-
Muang, Thailand, 12120
- Novartis Investigative Site
-
-
Nonthaburi
-
Taladkwan, Nonthaburi, Thailand, 11000
- Novartis Investigative Site
-
-
-
-
-
Adana, Turkey, 01250
- Novartis Investigative Site
-
Ankara, Turkey, 06100
- Novartis Investigative Site
-
Antalya, Turkey, 07070
- Novartis Investigative Site
-
Balcova / Izmir, Turkey, 35340
- Novartis Investigative Site
-
Edirne, Turkey, 22030
- Novartis Investigative Site
-
Etlik / Ankara, Turkey, 06018
- Novartis Investigative Site
-
Haseki / Istanbul, Turkey, 34096
- Novartis Investigative Site
-
Istanbul, Turkey, 34093
- Novartis Investigative Site
-
Istanbul, Turkey, 34304
- Novartis Investigative Site
-
Izmir, Turkey, 35040
- Novartis Investigative Site
-
Kocaeli, Turkey, 41380
- Novartis Investigative Site
-
Mersin, Turkey, 33079
- Novartis Investigative Site
-
Meselik / Eskisehir, Turkey, 26480
- Novartis Investigative Site
-
Sivas, Turkey, 58140
- Novartis Investigative Site
-
-
-
-
-
Birmingham, United Kingdom, B18 7QH
- Novartis Investigative Site
-
Blackpool, United Kingdom, FY3 8NR
- Novartis Investigative Site
-
Bournemouth, United Kingdom, BH7 7DW
- Novartis Investigative Site
-
Bradford, United Kingdom, BD9 6RJ
- Novartis Investigative Site
-
Cheshire, United Kingdom, CW1 4QJ
- Novartis Investigative Site
-
Coventry, United Kingdom, CV2 2DX
- Novartis Investigative Site
-
Croydon, United Kingdom, CR7 7YE
- Novartis Investigative Site
-
Darlington, United Kingdom, DL3 6HX
- Novartis Investigative Site
-
Exeter, United Kingdom, EX2 5AX
- Novartis Investigative Site
-
Inverness, United Kingdom, IV2 3UJ
- Novartis Investigative Site
-
Kent, United Kingdom, DA2 8DA
- Novartis Investigative Site
-
Liverpool, United Kingdom, L7 8XP
- Novartis Investigative Site
-
London, United Kingdom, W1G 8PH
- Novartis Investigative Site
-
Londonderry, United Kingdom, BT47 1SB
- Novartis Investigative Site
-
Manchester, United Kingdom, M13 9WL
- Novartis Investigative Site
-
Middlesborough, United Kingdom, TS4 3BW
- Novartis Investigative Site
-
Milton Keynes, United Kingdom, MK6 5LD
- Novartis Investigative Site
-
Newport, United Kingdom, NP20 2UB
- Novartis Investigative Site
-
Newport, United Kingdom, P030 5TG
- Novartis Investigative Site
-
Norwich, United Kingdom, NR4 7UY
- Novartis Investigative Site
-
Poole, United Kingdom, BH15 2JB
- Novartis Investigative Site
-
Rotherham, United Kingdom, S60 2OD
- Novartis Investigative Site
-
Stevenage, United Kingdom, SG1 4AB
- Novartis Investigative Site
-
Sunderland, United Kingdom, SR4 7TP
- Novartis Investigative Site
-
Surrey, United Kingdom, SM5 1AA
- Novartis Investigative Site
-
Vale of Glamorgan, United Kingdom, CF64 2XX
- Novartis Investigative Site
-
Worcester, United Kingdom, WR5 1DD
- Novartis Investigative Site
-
York, United Kingdom, YO31 8HE
- Novartis Investigative Site
-
-
Bs2 8hw
-
Bristol, Bs2 8hw, United Kingdom
- Novartis Investigative Site
-
-
Cambrigdeshire
-
Cambridge, Cambrigdeshire, United Kingdom, CB2 0QQ
- Novartis Investigative Site
-
-
County Durham
-
Durham, County Durham, United Kingdom, DH1 5TW
- Novartis Investigative Site
-
-
Dorset
-
Dorchester, Dorset, United Kingdom, DT1 2JY
- Novartis Investigative Site
-
-
East Sussex
-
Brighton, East Sussex, United Kingdom, BN2 5BE
- Novartis Investigative Site
-
-
England
-
Swansea, England, United Kingdom, SA6 6NL
- Novartis Investigative Site
-
-
Essex
-
Romford, Essex, United Kingdom, RM7 0AG
- Novartis Investigative Site
-
-
Hampshire
-
Basingstoke, Hampshire, United Kingdom, RG24 9NA
- Novartis Investigative Site
-
Portsmouth, Hampshire, United Kingdom, PO6 3LY
- Novartis Investigative Site
-
-
Kent
-
Royal Bridge Wells, Kent, United Kingdom, TN4 8AT
- Novartis Investigative Site
-
-
Lancashire
-
Oldham, Lancashire, United Kingdom, OL1 2JH
- Novartis Investigative Site
-
-
Leicestershire
-
Leicester, Leicestershire, United Kingdom, LE2 7LX
- Novartis Investigative Site
-
-
Northern Ireland
-
Craigavon, Northern Ireland, United Kingdom, BT63 5QQ
- Novartis Investigative Site
-
-
Perthshire
-
Dundee, Perthshire, United Kingdom, DD1 2BU
- Novartis Investigative Site
-
-
Somerset
-
Taunton, Somerset, United Kingdom, TA1 5DA
- Novartis Investigative Site
-
Yeovil, Somerset, United Kingdom, BA21 4AT
- Novartis Investigative Site
-
-
South Yorkshire
-
Sheffield, South Yorkshire, United Kingdom, S10 2JF
- Novartis Investigative Site
-
-
Surrey
-
Redhill, Surrey, United Kingdom, RH1 5RH
- Novartis Investigative Site
-
-
Tyne and Wear
-
South Shields, Tyne and Wear, United Kingdom, NE34 0PL
- Novartis Investigative Site
-
-
West Midlands
-
Dudley, West Midlands, United Kingdom, DY1 2HQ
- Novartis Investigative Site
-
Sutton Coldfield, West Midlands, United Kingdom, B75 7RR
- Novartis Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Novartis Investigative Site
-
Birmingham, Alabama, United States, 35211
- Novartis Investigative Site
-
Huntsville, Alabama, United States, 35801
- Novartis Investigative Site
-
Mobile, Alabama, United States, 36608
- Novartis Investigative Site
-
Muscle Shoals, Alabama, United States, 35662
- Novartis Investigative Site
-
-
Alaska
-
Anchorage, Alaska, United States, 99508
- Novartis Investigative Site
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Novartis Investigative Site
-
Phoenix, Arizona, United States, 85020
- Novartis Investigative Site
-
Phoenix, Arizona, United States, 85006
- Novartis Investigative Site
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72204
- Novartis Investigative Site
-
Little Rock, Arkansas, United States, 72205
- Novartis Investigative Site
-
-
California
-
Anaheim, California, United States, 92801
- Novartis Investigative Site
-
Bellflower, California, United States, 90706
- Novartis Investigative Site
-
Berkley, California, United States, 94705
- Novartis Investigative Site
-
Loma Linda, California, United States, 92357
- Novartis Investigative Site
-
Los Angeles, California, United States, 90033
- Novartis Investigative Site
-
Los Angeles, California, United States, 90073
- Novartis Investigative Site
-
Mather, California, United States, 95655
- Novartis Investigative Site
-
Oceanside, California, United States, 92056
- Novartis Investigative Site
-
Palm Springs, California, United States, 92262
- Novartis Investigative Site
-
Pomona, California, United States, 91767
- Novartis Investigative Site
-
Sacramento, California, United States, 95816
- Novartis Investigative Site
-
San Diego, California, United States, 92161
- Novartis Investigative Site
-
San Diego, California, United States, 92103
- Novartis Investigative Site
-
Santa Rosa, California, United States, 95405
- Novartis Investigative Site
-
Stockton, California, United States, 95204
- Novartis Investigative Site
-
Tustin, California, United States, 92780
- Novartis Investigative Site
-
-
Colorado
-
Denver, Colorado, United States, 80206
- Novartis Investigative Site
-
Denver, Colorado, United States, 80220
- Novartis Investigative Site
-
-
Connecticut
-
Stamford, Connecticut, United States, 06905
- Novartis Investigative Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20422
- Novartis Investigative Site
-
-
Florida
-
Boynton Beach, Florida, United States, 33472-2952
- Novartis Investigative Site
-
Davie, Florida, United States, 33324
- Novartis Investigative Site
-
Fort Lauderdale, Florida, United States, 33316
- Novartis Investigative Site
-
Gainesville, Florida, United States, 32608
- Novartis Investigative Site
-
Jacksonville, Florida, United States, 32216
- Novartis Investigative Site
-
Jacksonville, Florida, United States, 32223
- Novartis Investigative Site
-
Jacksonville, Florida, United States, 32209-6511
- Novartis Investigative Site
-
Lakeland, Florida, United States, 33805
- Novartis Investigative Site
-
Leesburg, Florida, United States, 34748
- Novartis Investigative Site
-
Port Charlotte, Florida, United States, 33952
- Novartis Investigative Site
-
Tamarac, Florida, United States, 33321
- Novartis Investigative Site
-
Tampa, Florida, United States, 33609
- Novartis Investigative Site
-
-
Georgia
-
Covington, Georgia, United States, 30014
- Novartis Investigative Site
-
Decatur, Georgia, United States, 30030
- Novartis Investigative Site
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- Novartis Investigative Site
-
Honolulu, Hawaii, United States, 96817
- Novartis Investigative Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Novartis Investigative Site
-
Maywood, Illinois, United States, 60153
- Novartis Investigative Site
-
Melrose Park, Illinois, United States, 60160
- Novartis Investigative Site
-
Park Ridge, Illinois, United States, 60068
- Novartis Investigative Site
-
Quincy, Illinois, United States, 62301
- Novartis Investigative Site
-
-
Iowa
-
Des Moines, Iowa, United States, 50314
- Novartis Investigative Site
-
-
Kansas
-
Pratt, Kansas, United States, 67124
- Novartis Investigative Site
-
Topeka, Kansas, United States, 66606
- Novartis Investigative Site
-
Wichita, Kansas, United States, 67207
- Novartis Investigative Site
-
-
Louisiana
-
Alexandria, Louisiana, United States, 71301
- Novartis Investigative Site
-
Covington, Louisiana, United States, 70433
- Novartis Investigative Site
-
Lafayette, Louisiana, United States, 70501
- Novartis Investigative Site
-
Slidell, Louisiana, United States, 70458
- Novartis Investigative Site
-
-
Maine
-
Biddeford, Maine, United States, 04005
- Novartis Investigative Site
-
South Portland, Maine, United States, 04106
- Novartis Investigative Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21208
- Novartis Investigative Site
-
Beltsville, Maryland, United States, 20705
- Novartis Investigative Site
-
Columbia, Maryland, United States, 21044
- Novartis Investigative Site
-
Nottingham, Maryland, United States, 21236
- Novartis Investigative Site
-
-
Massachusetts
-
Ayer, Massachusetts, United States, 01432
- Novartis Investigative Site
-
Boston, Massachusetts, United States
- Novartis Investigative Site
-
Haverhill, Massachusetts, United States, 01830
- Novartis Investigative Site
-
Natick, Massachusetts, United States, 01760
- Novartis Investigative Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- Novartis Investigative Site
-
Detroit, Michigan, United States, 48202
- Novartis Investigative Site
-
Lapeer, Michigan, United States, 48446
- Novartis Investigative Site
-
Saginaw, Michigan, United States, 48601
- Novartis Investigative Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55417
- Novartis Investigative Site
-
St. Paul, Minnesota, United States, 55102
- Novartis Investigative Site
-
-
Mississippi
-
Picayune, Mississippi, United States, 39466
- Novartis Investigative Site
-
Rolling Fork, Mississippi, United States, 39159
- Novartis Investigative Site
-
-
Missouri
-
Springfield, Missouri, United States, 65804
- Novartis Investigative Site
-
Springfield, Missouri, United States, 65807
- Novartis Investigative Site
-
-
Nebraska
-
Fremont, Nebraska, United States, 68025
- Novartis Investigative Site
-
Grand Island, Nebraska, United States, 68803
- Novartis Investigative Site
-
Omaha, Nebraska, United States, 68131
- Novartis Investigative Site
-
-
New Hampshire
-
Nashua, New Hampshire, United States, 03060
- Novartis Investigative Site
-
-
New Jersey
-
Elizabeth, New Jersey, United States, 07202
- Novartis Investigative Site
-
Hamilton, New Jersey, United States, 08690
- Novartis Investigative Site
-
New Brunswick, New Jersey, United States, 08901
- Novartis Investigative Site
-
Newark, New Jersey, United States, 07103-2714
- Novartis Investigative Site
-
Ocean, New Jersey, United States, 07712
- Novartis Investigative Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Novartis Investigative Site
-
-
New York
-
Cordtlandt Manor, New York, United States, 10567
- Novartis Investigative Site
-
Laurelton, New York, United States, 11422
- Novartis Investigative Site
-
New York, New York, United States, 10032
- Novartis Investigative Site
-
Northport, New York, United States, 11768
- Novartis Investigative Site
-
-
North Carolina
-
Asheboro, North Carolina, United States, 27204
- Novartis Investigative Site
-
Asheville, North Carolina, United States, 28803
- Novartis Investigative Site
-
Cary, North Carolina, United States, 27511
- Novartis Investigative Site
-
Greensboro, North Carolina, United States, 27401
- Novartis Investigative Site
-
Raleigh, North Carolina, United States, 27610
- Novartis Investigative Site
-
Wilmington, North Carolina, United States, 28401
- Novartis Investigative Site
-
-
Ohio
-
Cadiz, Ohio, United States, 43907
- Novartis Investigative Site
-
Canton, Ohio, United States, 44710
- Novartis Investigative Site
-
Cincinnati, Ohio, United States, 45219
- Novartis Investigative Site
-
Cincinnati, Ohio, United States, 45267-0585
- Novartis Investigative Site
-
Cleveland, Ohio, United States, 44195
- Novartis Investigative Site
-
Columbus, Ohio, United States, 43210
- Novartis Investigative Site
-
Marion, Ohio, United States, 43302
- Novartis Investigative Site
-
-
Oklahoma
-
Bartlesville, Oklahoma, United States, 74006
- Novartis Investigative Site
-
Oklahoma City, Oklahoma, United States, 73104
- Novartis Investigative Site
-
Oklahoma City, Oklahoma, United States, 73120
- Novartis Investigative Site
-
Stillwater, Oklahoma, United States, 74074
- Novartis Investigative Site
-
Tulsa, Oklahoma, United States, 74136
- Novartis Investigative Site
-
Tulsa, Oklahoma, United States, 74104-4243
- Novartis Investigative Site
-
-
Oregon
-
Portland, Oregon, United States, 97239-3098
- Novartis Investigative Site
-
-
Pennsylvania
-
Aliquippa, Pennsylvania, United States, 15001
- Novartis Investigative Site
-
Beaver, Pennsylvania, United States, 15009
- Novartis Investigative Site
-
Philadelphia, Pennsylvania, United States, 19102-1192
- Novartis Investigative Site
-
Pittsburgh, Pennsylvania, United States, 15206
- Novartis Investigative Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29401-5799
- Novartis Investigative Site
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Novartis Investigative Site
-
-
Tennessee
-
Memphis, Tennessee, United States, 38104
- Novartis Investigative Site
-
Nashville, Tennessee, United States, 37203
- Novartis Investigative Site
-
Nashville, Tennessee, United States, 37212
- Novartis Investigative Site
-
-
Texas
-
Amarillo, Texas, United States, 79106
- Novartis Investigative Site
-
Arlington, Texas, United States, 76012
- Novartis Investigative Site
-
Beaumont, Texas, United States, 77702
- Novartis Investigative Site
-
Beaumont, Texas, United States, 77701
- Novartis Investigative Site
-
Brownsville, Texas, United States, 78520
- Novartis Investigative Site
-
Dallas, Texas, United States, 75235
- Novartis Investigative Site
-
Dallas, Texas, United States, 75231
- Novartis Investigative Site
-
Dallas, Texas, United States, 75390
- Novartis Investigative Site
-
Dallas, Texas, United States, 75251
- Novartis Investigative Site
-
Grapevine, Texas, United States, 76051
- Novartis Investigative Site
-
Houston, Texas, United States, 77030
- Novartis Investigative Site
-
Houston, Texas, United States, 77025
- Novartis Investigative Site
-
Houston, Texas, United States, 77081
- Novartis Investigative Site
-
Houston, Texas, United States, 77024
- Novartis Investigative Site
-
Houston, Texas, United States, 77070
- Novartis Investigative Site
-
Kingwood, Texas, United States, 77339
- Novartis Investigative Site
-
Livingston, Texas, United States, 77351
- Novartis Investigative Site
-
Lufkin, Texas, United States, 75904
- Novartis Investigative Site
-
Odessa, Texas, United States, 79761
- Novartis Investigative Site
-
Plano, Texas, United States, 75024
- Novartis Investigative Site
-
Tyler, Texas, United States, 75701
- Novartis Investigative Site
-
-
Utah
-
Layton, Utah, United States, 84041
- Novartis Investigative Site
-
-
Virginia
-
Fredericksburg, Virginia, United States, 22401
- Novartis Investigative Site
-
Richmond, Virginia, United States, 23219
- Novartis Investigative Site
-
Richmond, Virginia, United States, 23249
- Novartis Investigative Site
-
-
Washington
-
Seattle, Washington, United States, 98103
- Novartis Investigative Site
-
Spokane, Washington, United States, 99204
- Novartis Investigative Site
-
Tacoma, Washington, United States, 98405
- Novartis Investigative Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792-1615
- Novartis Investigative Site
-
Milwaukee, Wisconsin, United States, 53295
- Novartis Investigative Site
-
Waukesha, Wisconsin, United States, 53188
- Novartis Investigative Site
-
Wausau, Wisconsin, United States, 54401
- Novartis Investigative Site
-
-
-
-
Distrito Capital
-
Caracas, Distrito Capital, Venezuela, 1060
- Novartis Investigative Site
-
-
Estado Miranda
-
Caracas, Estado Miranda, Venezuela, 1061
- Novartis Investigative Site
-
-
Estado Monagas
-
Maturin, Estado Monagas, Venezuela, 6201
- Novartis Investigative Site
-
-
Estado Zulia
-
Maracaibo, Estado Zulia, Venezuela, 4011
- Novartis Investigative Site
-
Maracaibo, Estado Zulia, Venezuela
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must give written informed consent before any assessment is performed.
- Outpatients ≥ 18 years of age, male or female.
- Patients with a diagnosis of CHF NYHA class II-IV and reduced ejection fraction (EF =< 35%) and elevated BNP.
- Patients must be on an ACEI or an ARB at a stable dose of at least enalapril 10 mg/d or equivalent for at least 4 weeks.
- Patients must be treated with a β-blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks.
Exclusion Criteria:
- Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
- History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACEIs, ARBs, or NEP inhibitors as well as known or suspected contraindications to the study drugs.
- Previous history of intolerance to recommended target doses of ACEIs or ARBs
- Known history of angioedema.
- Requirement of treatment with both ACEIs and ARBs.
- Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy).
- Symptomatic hypotension and/or a SBP < 100 mmHg.
- Estimated GFR < 30 mL/min/1.73m2 as measured by the simplified MDRD formula
- Serum potassium > 5.2 mmol/L.
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: LCZ696
single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks.
Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization.
LCZ696 200mg BID during double blind treatment period
|
LCZ696 200 mg BID
|
|
Active Comparator: Enalapril
single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks.
Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization.
Enalapril 10 mg BID during double blind treatment period
|
Enalapril 10 mg BID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization
Time Frame: up to 51 months
|
Number of participants that had first occurrence of the composite endpoint, which is defined as either CV death or HF hospitalization due to HF.
|
up to 51 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients - All-cause Mortality
Time Frame: up to 51 months
|
Number of patients - All-cause mortality.
All-cause mortality is common in Heart Failure HF patients this measures how many patients had this event.
The data is on FAS population up to March 31, 2014
|
up to 51 months
|
|
Number of Patients Reported With Adjudicated Primary Causes of Death
Time Frame: up to 51 months
|
Number of patients reported with adjudicated primary causes of death.
The data is on Randomization population up to March 31, 2014
|
up to 51 months
|
|
Change From Baseline to Month 8 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score
Time Frame: Baseline, Month 8
|
Change from baseline to Month 8 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score.
KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.
KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores.
Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
|
Baseline, Month 8
|
|
Number of Patients With First Confirmed Renal Dysfunction
Time Frame: up to 51 months
|
Number of patients with first confirmed renal dysfunction
|
up to 51 months
|
|
Percentage of Participants With New Onset of Atrial Fibrillation (AF)
Time Frame: up to 51 months
|
Percentage of participants with New Onset of Atrial Fibrillation The new onset atrial fibrillation (AF) analysis was based on a subset of FAS: i.e., for patients without a history of AF at baseline (patients with a history of AF were excluded from this analysis).
|
up to 51 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Vaduganathan M, Claggett BL, McMurray JJV, Solomon SD. Health Status Trajectories Before and After Hospitalization for Heart Failure. Circulation. 2022 Jun 21;145(25):1872-1874. doi: 10.1161/CIRCULATIONAHA.122.059282. Epub 2022 May 21. No abstract available.
- Shen L, Jhund PS, Anand IS, Bhatt AS, Desai AS, Maggioni AP, Martinez FA, Pfeffer MA, Rizkala AR, Rouleau JL, Swedberg K, Vaduganathan M, Vardeny O, van Veldhuisen DJ, Zannad F, Zile MR, Packer M, Solomon SD, McMurray JJV. Incidence and Outcomes of Pneumonia in Patients With Heart Failure. J Am Coll Cardiol. 2021 Apr 27;77(16):1961-1973. doi: 10.1016/j.jacc.2021.03.001.
- Solomon SD, Vaduganathan M, L Claggett B, Packer M, Zile M, Swedberg K, Rouleau J, A Pfeffer M, Desai A, Lund LH, Kober L, Anand I, Sweitzer N, Linssen G, Merkely B, Luis Arango J, Vinereanu D, Chen CH, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJV. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020 Feb 4;141(5):352-361. doi: 10.1161/CIRCULATIONAHA.119.044586. Epub 2019 Nov 17.
- Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, Lefkowitz MP, Shi VC, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV, Solomon SD; PARAGON-HF Investigators. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019 Oct;7(10):862-874. doi: 10.1016/j.jchf.2019.05.015. Epub 2019 Jul 10.
- Andersen MB, Simonsen U, Wehland M, Pietsch J, Grimm D. LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):14-22. doi: 10.1111/bcpt.12453. Epub 2015 Sep 4.
- Shen L, Claggett BL, Jhund PS, Abraham WT, Desai AS, Dickstein K, Gong J, Kober LV, Lefkowitz MP, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, McMurray JJV. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clin Res Cardiol. 2021 Aug;110(8):1334-1349. doi: 10.1007/s00392-021-01888-x. Epub 2021 Jun 8.
- Kristensen SL, Castagno D, Shen L, Jhund PS, Docherty KF, Rorth R, Abraham WT, Desai AS, Dickstein K, Rouleau JL, Zile MR, Swedberg K, Packer M, Solomon SD, Kober L, McMurray JJV; PARADIGM-HF and ATMOSPHERE Committees and Investigators.. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail. 2020 Dec;22(12):2370-2379. doi: 10.1002/ejhf.1972. Epub 2020 Sep 14.
- Docherty KF, Shen L, Castagno D, Petrie MC, Abraham WT, Bohm M, Desai AS, Dickstein K, Kober LV, Packer M, Rouleau JL, Solomon SD, Swedberg K, Vazir A, Zile MR, Jhund PS, McMurray JJV. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020 Mar;22(3):528-538. doi: 10.1002/ejhf.1682. Epub 2019 Dec 17.
- Dewan P, Rorth R, Raparelli V, Campbell RT, Shen L, Jhund PS, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Kober L, Komajda M, McKelvie RS, O'Meara E, Pfeffer MA, Pitt B, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 Dec;12(12):e006539. doi: 10.1161/CIRCHEARTFAILURE.119.006539. Epub 2019 Dec 9. Erratum In: Circ Heart Fail. 2020 Jan;13(1):e000036.
- Shen L, Ramires F, Martinez F, Bodanese LC, Echeverria LE, Gomez EA, Abraham WT, Dickstein K, Kober L, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Jhund PS, Gimpelewicz CR, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators and Committees. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017 Nov;10(11):e004361. doi: 10.1161/CIRCHEARTFAILURE.117.004361.
- Kristensen SL, Jhund PS, Mogensen UM, Rorth R, Abraham WT, Desai A, Dickstein K, Rouleau JL, Zile MR, Swedberg K, Packer M, Solomon SD, Kober L, McMurray JJV; PARADIGM-HF and ATMOSPHERE Committees and Investigators. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ Heart Fail. 2017 Oct;10(10):e004409. doi: 10.1161/CIRCHEARTFAILURE.117.004409.
- Toenges G, Mutze T, Jahn-Eimermacher A. A comparison of semiparametric approaches to evaluate composite endpoints in heart failure trials. Stat Med. 2021 Nov 20;40(26):5702-5724. doi: 10.1002/sim.9149. Epub 2021 Jul 30.
- Ehteshami-Afshar S, Mooney L, Dewan P, Desai AS, Lang NN, Lefkowitz MP, Petrie MC, Rizkala AR, Rouleau JL, Solomon SD, Swedberg K, Shi VC, Zile MR, Packer M, McMurray JJV, Jhund PS, Hawkins NM. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 Feb 16;10(4):e019238. doi: 10.1161/JAHA.120.019238. Epub 2021 Jan 30.
- Selvaraj S, Claggett B, Pozzi A, McMurray JJV, Jhund PS, Packer M, Desai AS, Lewis EF, Vaduganathan M, Lefkowitz MP, Rouleau JL, Shi VC, Zile MR, Swedberg K, Solomon SD. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation. 2019 Oct 22;140(17):1369-1379. doi: 10.1161/CIRCULATIONAHA.119.039920. Epub 2019 Sep 12.
- Balmforth C, Simpson J, Shen L, Jhund PS, Lefkowitz M, Rizkala AR, Rouleau JL, Shi V, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC Heart Fail. 2019 Jun;7(6):457-465. doi: 10.1016/j.jchf.2019.02.015. Epub 2019 May 8.
- Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol. 2019 Mar 26;73(11):1264-1272. doi: 10.1016/j.jacc.2019.01.018. Epub 2019 Mar 4.
- Zile MR, O'Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, Packer M, McMurray JJV, Shi V, Lefkowitz M, Rouleau J. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. J Am Coll Cardiol. 2019 Feb 26;73(7):795-806. doi: 10.1016/j.jacc.2018.11.042.
- Bouabdallaoui N, Claggett B, Zile MR, McMurray JJV, O'Meara E, Packer M, Prescott MF, Swedberg K, Solomon SD, Rouleau JL; PARADIGM-HF Investigators and Committees. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2018 Dec;20(12):1701-1709. doi: 10.1002/ejhf.1301. Epub 2018 Sep 11.
- O'Meara E, Prescott MF, Claggett B, Rouleau JL, Chiang LM, Solomon SD, Packer M, McMurray JJV, Zile MR. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 May;11(5):e004446. doi: 10.1161/CIRCHEARTFAILURE.117.004446.
- Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018 Jul;6(7):547-554. doi: 10.1016/S2213-8587(18)30100-1. Epub 2018 Apr 13.
- Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, Swedberg K, Rouleau JL, Shi VC, Lefkowitz MP, Katova T, McMurray JJV, Solomon SD. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2018 Jun 1;3(6):498-505. doi: 10.1001/jamacardio.2018.0398.
- Lewis EF, Claggett BL, McMurray JJV, Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Zile MR, Desai AS, Solomon SD, Swedberg K. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail. 2017 Aug;10(8):e003430. doi: 10.1161/CIRCHEARTFAILURE.116.003430.
- Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong J, Shi VC, Solomon SD. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016 Dec 6;68(22):2425-2436. doi: 10.1016/j.jacc.2016.09.931.
- Nadruz W Jr, Claggett BL, McMurray JJ, Packer M, Zile MR, Rouleau JL, Desai AS, Swedberg K, Lefkowitz M, Shi VC, Prescott MF, Solomon SD. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation. 2016 Nov 29;134(22):1785-1787. doi: 10.1161/CIRCULATIONAHA.116.024976. No abstract available.
- Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V, Solomon SD. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017 Jan 1;2(1):79-85. doi: 10.1001/jamacardio.2016.4733.
- Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ; PARADIGM-HF Investigators and Committees*. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. Circ Heart Fail. 2016 Sep;9(9):e003212. doi: 10.1161/CIRCHEARTFAILURE.116.003212.
- Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, Rouleau J, Shi V, Lefkowitz M, McMurray JJV. Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. JACC Heart Fail. 2016 Oct;4(10):816-822. doi: 10.1016/j.jchf.2016.05.002. Epub 2016 Jul 6.
- Kristensen SL, Martinez F, Jhund PS, Arango JL, Belohlavek J, Boytsov S, Cabrera W, Gomez E, Hagege AA, Huang J, Kiatchoosakun S, Kim KS, Mendoza I, Senni M, Squire IB, Vinereanu D, Wong RC, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJ. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J. 2016 Nov 1;37(41):3167-3174. doi: 10.1093/eurheartj/ehw226. Epub 2016 Jun 28.
- Desai AS, Solomon S, Claggett B, McMurray JJ, Rouleau J, Swedberg K, Zile M, Lefkowitz M, Shi V, Packer M. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circ Heart Fail. 2016 Jun;9(6):e002735. doi: 10.1161/CIRCHEARTFAILURE.115.002735.
- Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ; PARADIGM-HF Investigators and Committees*. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016 Jun 7;133(23):2254-62. doi: 10.1161/CIRCULATIONAHA.115.020729. Epub 2016 Apr 20.
- Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan O, Dukat A, Lefkowitz MP, McMurray JJ. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016 Mar;9(3):e002744. doi: 10.1161/CIRCHEARTFAILURE.115.002744.
- Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M; PARADIGM-HF Investigators and Committees. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016 Jan;9(1):e002560. doi: 10.1161/CIRCHEARTFAILURE.115.002560.
- Simpson J, Jhund PS, Silva Cardoso J, Martinez F, Mosterd A, Ramires F, Rizkala AR, Senni M, Squire I, Gong J, Lefkowitz MP, Shi VC, Desai AS, Rouleau JL, Swedberg K, Zile MR, McMurray JJV, Packer M, Solomon SD; PARADIGM-HF Investigators and Committees. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015 Nov 10;66(19):2059-2071. doi: 10.1016/j.jacc.2015.08.878.
- Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M; PARADIGM-HF Investigators and Committees. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015 Oct 7;36(38):2576-84. doi: 10.1093/eurheartj/ehv330. Epub 2015 Jul 31.
- Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, Gong J, Rizkala AR, Brahimi A, Claggett B, Finn PV, Hartley LH, Liu J, Lefkowitz M, Shi V, Zile MR, Solomon SD. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015 Aug 7;36(30):1990-7. doi: 10.1093/eurheartj/ehv186. Epub 2015 May 28.
- McMurray J, Packer M, Desai A, Gong J, Greenlaw N, Lefkowitz M, Rizkala A, Shi V, Rouleau J, Solomon S, Swedberg K, Zile MR, Andersen K, Arango JL, Arnold M, Belohlavek J, Bohm M, Boytsov S, Burgess L, Cabrera W, Chen CH, Erglis A, Fu M, Gomez E, Gonzalez A, Hagege AA, Katova T, Kiatchoosakun S, Kim KS, Bayram E, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires F, Refsgaard J, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire I, Starling RC, Vinereanu D, Teerlink JR, Wong R; PARADIGM-HF Committees and Investigators. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015 Feb 14;36(7):434-9. doi: 10.1093/eurheartj/ehu455.
- Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Belohlavek J, Bohm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzalez-Medina A, Hagege AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan O, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015 Jan 6;131(1):54-61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17.
- McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.
- McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013 Sep;15(9):1062-73. doi: 10.1093/eurjhf/hft052. Epub 2013 Apr 5.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2009
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
December 16, 2009
First Submitted That Met QC Criteria
December 17, 2009
First Posted (Estimate)
December 18, 2009
Study Record Updates
Last Update Posted (Estimate)
August 15, 2016
Last Update Submitted That Met QC Criteria
July 13, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Heart Failure
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Enalapril
- Sacubitril and valsartan sodium hydrate drug combination
Other Study ID Numbers
- CLCZ696B2314
- 2009-015834-31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure With Reduced Ejection Fraction
-
Xinjiang Medical UniversityNot yet recruitingChronic Heart Failure | Heart Failure With Reduced Ejection Fraction (HFrEF) | Heart Failure With Preserved Ejection Fraction (HFPEF) | Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)China
-
IRCCS Policlinico S. DonatoAgenzia Italiana del FarmacoNot yet recruitingHeart Failure | Acute Heart Failure | Heart Failure With Reduced Ejection Fraction (HFrEF) | Heart Failure With Preserved Ejection Fraction (HFPEF) | Heart Failure With Mildly Reduced Ejection FractionItaly
-
SateliaCentral Hospital, Nancy, FranceCompletedHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction (HFPEF) | Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)France
-
Linkoeping UniversityRecruitingHeart Failure With Reduced Ejection FractionSweden
-
Medical University of SilesiaRecruitingHeart Failure With Reduced Ejection FractionPoland
-
Beijing Anzhen HospitalThe First Hospital of Jilin University; Second Affiliated Hospital of Nanchang...Recruiting
-
Novartis PharmaceuticalsActive, not recruitingHeart Failure With Reduced Ejection FractionRomania
-
Wroclaw Medical UniversityNot yet recruitingChronic Heart Failure With Reduced Ejection FractionPoland
-
Heinrich-Heine University, DuesseldorfNot yet recruiting
-
Azienda Unita Sanitaria Locale di PiacenzaRecruitingHeart Failure With Reduced Ejection Fraction (HFrEF)Italy
Clinical Trials on LCZ696 200 mg BID
-
Innovation Pharmaceuticals, Inc.CompletedChronic Stable Plaque PsoriasisUnited States
-
Guangzhou JOYO Pharma Co., LtdRecruitingLung Neoplasms | Brain Neoplasms | Protein Kinase Inhibitors | Other Protocol Specified CriteriaChina
-
Novartis PharmaceuticalsCompleted
-
CTI BioPharmaPPD Development, LPCompleted
-
Hoffmann-La RocheCompletedChronic Hepatitis CUnited States, Puerto Rico
-
N-Gene Research Laboratories, Inc.Thermo Fisher Scientific, Inc; Integrium; Msource Medical Development GmbH; Kinexum... and other collaboratorsTerminatedDiabetes MellitusUnited States, Germany, Hungary
-
Hamamatsu UniversityCompletedGastritis Associated With Helicobacter PyloriJapan
-
Kadmon, a Sanofi CompanyCompletedChronic Graft-versus-host-diseaseUnited States
-
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Completed
-
MedPacto, Inc.TerminatedCarcinoma, Non-Small-Cell LungKorea, Republic of